FDG PET in suspected recurrent and metastatic prostate cancer

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1485-1488

  Jadvar, Hossein ^a   Pinski, Jacek K ^a   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; FDG; PET; Prostate

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ARTICLE; CANCER INVASION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; RECURRENT DISEASE; SCINTISCANNING;

AGED; AGED, 80 AND OVER; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECURRENCE; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 2142743306     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1485     Document Type: Article

References (29)

1. Frank IN, Graham S Jr and Nabors WL: Urologie and male genital cancers. In: Clinical Oncology. Holleb AI, Fink DJ and Murphy GP (eds.) American Cancer Society, Atlanta, pp280-283, 1991.
2. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST and Bading JR: PET and [F-18]-FDG in oncology: a clinical update. Nucl Med Biol 23: 717-735, 1996. (Pubitemid 26342475)
3. Fischman AJ: Positron emission tomography in the clinical evaluation of metastatic cancer. J Clin Oncol 14: 691-696, 1996.
4. Jadvar H and Fischman AJ: Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography. Clin Positron Imaging 2: 153-158, 1999.
5. Kanamaru H, Oyama N, Akino J and Okada K: Evaluation of prostate cancer using FDG-PET. Hinyokika Kiyo 46: 851-853, 2000. (Pubitemid 32049922)
6. Liu IJ, Zafar MB, Lai YH, Segall GM and Terris MK: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57: 108-111, 2001.
7. Oyama N, Akino H, Kanamaru H and Okada K: FDG PET in diagnosis of untreated prostate cancer. Nippon Rinsho 56: 2052-2055, 1998.
8. Shreve PD, Grossman HB, Gross MD and Wahl RL: Metastatic prostate cancer: initial findings of PET with FDG. Radiology 199: 751-756, 1996.
9. Shvarts O, Han KR, Seltzer M, Pantuck AJ and Belldegrun AS: Positron emission tomography in urologie oncology. Cancer Control 9: 335-342, 2002. (Pubitemid 34921039)
10. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R and Schwaiger M: Fluorine- 18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 36: 31-35, 1999. (Pubitemid 29265277)
11. Agus DB, Golde DW, Sgouros G, Ballangrud A, Cordon-Cardo C and Scher HI: PET of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res 58: 3009-3014, 1998. (Pubitemid 28335080)
12. Effert PJ, Bares R, Handt S, Wolff JM, Bull U and Jakse G: Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol 155: 994-998, 1996.
13. Haberkorn U, Bellemann ME, Altmann A, Gerlach L, Morr I, Oberdorfer F, Brix G, Doll J, Blatter J and van Kaick G: PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med 38: 1215-1221, 1997. (Pubitemid 27332617)
14. Heicappell R, Muller-Mattheis V, Reinhardt M, Vosberg H, Gerharz CD, Muller-Gartner H and Ackermann R: Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 36: 582-587, 1999. (Pubitemid 29516289)
15. Morris NJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, Larson SM and Scher HI: Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 59: 913-918, 2002. (Pubitemid 34522186)
16. 18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 29: 623-629, 1999.
17. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K and Okada K: C-11 acetate PET imaging of prostate cancer. J Nucl Med 43: 181-186, 2002. (Pubitemid 34151040)
18. Patel P, Cohade C, De Weese T and Wahl RL: Evaluation of metabolic activity of prostate gland with PET-CT. J Nucl Med 43(Suppl 5): 119P, 2002.
19. Sanz G, Robles JE, Gimenez M, Arocena J, Sanchez D, Rodriguez-Rubio F, Rosell D, Richter JA and Berian JM: Positron emission tomography with 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84: 1028-1031, 1999.
20. Shimizu N, Masuda H, Yamanaka H, Oriuchi N, Inoue T and Endo K: Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy. J Urol 161: 608-609, 1999.
21. Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, Finn RD, Reddy D, Horowitz SM, Goldsmith SJ and Scher HI: Detection of bone metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 23: 693-697, 1996. (Pubitemid 26342473)
22. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS and Höh CK: Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 162: 1322-1328, 1999. (Pubitemid 29428572)
23. Jadvar H and Conti PS: Diagnostic utility of FDG-PET in multiple myeloma. Skeletal Radiol 31: 690-694, 2002. (Pubitemid 36104567)
24. Hara T, Kosaka N and Kishi H: Development of F-18 fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43: 187-199, 2002. (Pubitemid 34151041)
25. Hara T, Kosaka N and Kishi H: PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39: 990-995, 1998. (Pubitemid 28270113)
26. Nunez R, Macapinlac HA, Yeung H, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI and Larson SM: Combined FDG and C-11 methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43: 46-55, 2002. (Pubitemid 34101187)
27. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, Sadato N, Yonekura Y and Okada K: FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 22: 963-969, 2001. (Pubitemid 32783446)
28. 18F] FDG with PET in recurrence of prostate cancer. Am J Roentgenol 179: 482-484, 2002.
29. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 168: 273-280, 2002.